The EARLY-NEURO substudy aims to examine whether earlier neuroprognostication could be performed safely at 24 hours after randomization in patients with severe brain injury and whether the level of sedation may influence accuracy of examinations. Patients included from selected STEPCARE sites will be examined with brain CT and EEG if still unconscious at 24 hours. Blood samples will be collected routinely at 12, 24, 48 and 72 hours in all patients for the biomarker substudy. In accordance with ERC/ESICM guidelines and STEPCARE protocol, withdrawal of treatment for neurological reasons is discouraged until at least 72 hours have passed.


For introduction video, please enter password 'stepcare'. 


Including background, hypothesis, methods and eligibility criteria

19 Mar 2024 ‐ EARLY-NEURO
19 Mar 2024 ‐ EARLY-NEURO